MX364929B - Derivados de la 5-amino-quinolina-8-carboxamida como agonistas del receptor 5-ht4. - Google Patents

Derivados de la 5-amino-quinolina-8-carboxamida como agonistas del receptor 5-ht4.

Info

Publication number
MX364929B
MX364929B MX2015012350A MX2015012350A MX364929B MX 364929 B MX364929 B MX 364929B MX 2015012350 A MX2015012350 A MX 2015012350A MX 2015012350 A MX2015012350 A MX 2015012350A MX 364929 B MX364929 B MX 364929B
Authority
MX
Mexico
Prior art keywords
receptor agonists
quinoline
amino
carboxamide derivatives
formula
Prior art date
Application number
MX2015012350A
Other languages
English (en)
Other versions
MX2015012350A (es
Inventor
Venkateswarlu Jasti
Ramakrishna Nirogi
Anil Karbhari Shinde
Original Assignee
Suven Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suven Life Sciences Ltd filed Critical Suven Life Sciences Ltd
Publication of MX2015012350A publication Critical patent/MX2015012350A/es
Publication of MX364929B publication Critical patent/MX364929B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/558—Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/82—Translation products from oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Epidemiology (AREA)

Abstract

La presente invención describe novedosos compuestos de la quinolina de la fórmula (I), y sus sales y procesos de preparación farmacéuticamente aceptables. (ver Fórmula) Los compuestos de la fórmula (I) son útiles en el tratamiento de diversos trastornos que se relacionan con agonistas del receptor 5-HT4.
MX2015012350A 2013-03-20 2013-10-18 Derivados de la 5-amino-quinolina-8-carboxamida como agonistas del receptor 5-ht4. MX364929B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/IN2013/000639 WO2014147636A1 (en) 2013-03-20 2013-10-18 5-amino-quinoline-8-carboxamide derivatives as 5-ht4 receptor agonists
IN1199CH2013 IN2013CH01199A (es) 2013-03-20 2013-10-18

Publications (2)

Publication Number Publication Date
MX2015012350A MX2015012350A (es) 2016-05-09
MX364929B true MX364929B (es) 2019-05-14

Family

ID=54325095

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015012350A MX364929B (es) 2013-03-20 2013-10-18 Derivados de la 5-amino-quinolina-8-carboxamida como agonistas del receptor 5-ht4.

Country Status (19)

Country Link
US (1) US9790211B2 (es)
EP (1) EP2976337B1 (es)
JP (1) JP6185650B2 (es)
KR (1) KR101815307B1 (es)
CN (1) CN105164119B (es)
AP (1) AP2015008742A0 (es)
AU (1) AU2013382944B2 (es)
BR (1) BR112015024060A2 (es)
CA (1) CA2907620C (es)
DK (1) DK2976337T3 (es)
EA (1) EA029365B1 (es)
ES (1) ES2674993T3 (es)
HK (1) HK1217483A1 (es)
IN (1) IN2013CH01199A (es)
MX (1) MX364929B (es)
NZ (1) NZ712369A (es)
SG (1) SG11201507763RA (es)
WO (1) WO2014147636A1 (es)
ZA (1) ZA201506804B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3265459T (lt) * 2015-02-13 2019-08-26 Suven Life Sciences Limited Amidų junginiai, kaip 5-ht4 receptorių agonistai
CN109444301A (zh) * 2018-12-18 2019-03-08 江苏省中医院 一种测定血浆中普芦卡必利浓度的方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08502273A (ja) * 1992-10-13 1996-03-12 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー ５−ｈｔ▲下４▼レセプターアンタゴニスト用複素環式エステルまたはアミド
EP0667867A1 (en) 1992-11-05 1995-08-23 Smithkline Beecham Plc Piperidine derivatives as 5-ht4 receptor antagonists
FR2756564B1 (fr) * 1996-12-04 2004-05-14 Synthelabo Derives d'acide quinoleine-8-carboxylique, leur preparation et leur application en therapeutique
AU2001225663A1 (en) * 2000-06-15 2001-12-24 Respiratorius Ab A composition comprising a combination of receptor agonists and antagonists
ES2293262T3 (es) * 2003-06-19 2008-03-16 Janssen Pharmaceutica N.V. 4-(aminometil)-piperidin benzamidas 5ht4-antagonistas.
CA2545092C (en) 2003-11-24 2010-08-17 Pfizer Inc. Quinolonecarboxylic acid compounds having 5-ht4 receptor agonistic activity
DK1701951T3 (da) * 2003-12-23 2010-06-07 Serodus As Modulatorer af perifere 5-HT receptorer
WO2005092882A1 (en) * 2004-03-01 2005-10-06 Pfizer Japan, Inc. 4-amino-5-halogeno-benzamide derivatives as 5-ht4 receptor agonists for the treatment of gastrointestinal, cns, neurological and cardiovascular disorders
JP4970290B2 (ja) 2005-02-25 2012-07-04 ファイザー株式会社 ベンズイソキサゾール誘導体
EP1910340B1 (en) 2005-07-22 2009-11-18 Pfizer, Inc. Indazolecarboxamide derivatives as 5ht4 receptor agonists
GB0525661D0 (en) * 2005-12-16 2006-01-25 Glaxo Group Ltd Novel compounds
CN102753172A (zh) * 2010-02-12 2012-10-24 拉夸里亚创药株式会社 用于治疗痴呆的5-ht4受体激动剂
WO2011101774A1 (en) 2010-02-16 2011-08-25 Pfizer Inc. (r)-4-((4-((4-(tetrahydrofuran-3-yloxy)benzo[d]isoxazol-3-yloxy)methyl)piperidin-1-yl)methyl)tetrahydro-2h-pyran-4-ol, a partial agonist of 5-ht4 receptors

Also Published As

Publication number Publication date
BR112015024060A2 (pt) 2017-07-18
IN2013CH01199A (es) 2015-08-14
ZA201506804B (en) 2016-07-27
CN105164119A (zh) 2015-12-16
EA029365B1 (ru) 2018-03-30
AU2013382944B2 (en) 2016-08-04
JP2016516089A (ja) 2016-06-02
EP2976337B1 (en) 2018-05-02
CN105164119B (zh) 2017-12-08
WO2014147636A1 (en) 2014-09-25
MX2015012350A (es) 2016-05-09
DK2976337T3 (en) 2018-07-16
KR101815307B1 (ko) 2018-01-04
WO2014147636A8 (en) 2014-12-04
US9790211B2 (en) 2017-10-17
NZ712369A (en) 2016-11-25
SG11201507763RA (en) 2015-10-29
CA2907620A1 (en) 2014-09-25
AP2015008742A0 (en) 2015-09-30
EA201591844A1 (ru) 2016-08-31
ES2674993T3 (es) 2018-07-05
JP6185650B2 (ja) 2017-08-23
US20160280694A1 (en) 2016-09-29
HK1217483A1 (zh) 2017-01-13
CA2907620C (en) 2018-03-13
AU2013382944A1 (en) 2015-10-08
KR20160004274A (ko) 2016-01-12
EP2976337A1 (en) 2016-01-27

Similar Documents

Publication Publication Date Title
PH12019501321B1 (en) Use of pyrazolopyrimidine derivatives for the treatment of pi3k-delta related disorders
PH12018502125A1 (en) Bipyrazole derivatives as jak inhibitors
MX2016011632A (es) Derivados de azaspiro como antagonistas de trpm8.
MX2013008431A (es) Antagonista del receptor de mineralocorticoides.
WO2014155300A3 (en) Substitued pyrimidine amine derivatives as tak-1 inhibitors
EA201590183A1 (ru) Производные азаиндола, выступающие в качестве ингибиторов pi3k
PH12016500985A1 (en) Use of benzimidazole-proline derivatives
NZ706591A (en) Oxazolidin-2-one-pyrimidine derivatives
MX2016005759A (es) Derivados de piridina sustituidos, utiles como inhibidores de glucogeno sintasa cinasa 3 (gsk-3).
EA032271B9 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
PH12017500089A1 (en) Aldosterone synthase inhibitors
MX2016009621A (es) Derivados de fur0-3-carboxamida y metodos de uso.
EA201790830A1 (ru) Ингибиторы альдостеронсинтазы
MY176521A (en) Pyrrole-substituted indolone derivative, preparation method therefor, composition comprising the same and use thereof
MX2015012343A (es) Derivados de piridina sustituidos útiles como inhibidores de c-fms quinasa.
MX2013013436A (es) Derivados de indol sustituidos para el tratamiento de transtornos inmunologicos.
MX364929B (es) Derivados de la 5-amino-quinolina-8-carboxamida como agonistas del receptor 5-ht4.
NZ720879A (en) Indazole compounds as 5-ht4 receptor agonists
MX2015000064A (es) Compuestos de acrilamida como ligandos receptores de histamina h3.
PH12015502703A1 (en) Pharmaceutical compositions
IN2013MU03838A (es)
MX2015012393A (es) Derivados oxindol con un sustituyente oxetano y uso de los mismos para tratar enfermedades relacionadas con la vasopresina.

Legal Events

Date Code Title Description
FG Grant or registration